Search

DiagnoCure announces the filing of a preliminary prospectus

/NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR DISSEMINATION IN THE
UNITED STATES/
Ticker Symbol: CUR
QUEBEC CITY, March 21 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR)
("DiagnoCure") is pleased to announce that it has filed a preliminary short
form prospectus with the securities authorities in all provinces of Canada in
connection with the previously announced public offering of 5,850,000 common
shares in the share capital of DiagnoCure.
In addition, DiagnoCure has entered into an underwriting agreement with a
syndicate of underwriters led by National Bank Financial Inc. and including
Orion Securities Inc., Canaccord Capital Corporation and Industrial Alliance
Securities Inc. for the offering of the common shares. The underwriters have
been granted an option (the "Over-allotment Option") to sell that number of
additional common shares as is equal to 15% of the size of the offering for
market stabilization and over-allotment purposes. The Over-allotment Option
may be exercised at any time, in whole or in part, until that date which is
30 days following the closing date.
The offering is subject to normal regulatory approvals including approval
of the Toronto Stock Exchange and is expected to close on or before April 3,
2007.
The proceeds from the offering will be used to support the implementation
of the Company's business plan, namely to expand the product portfolio and
acquire or in-license additional cancer diagnostic products.
The securities offered have not been registered under the United States
Securities Act of 1933, as amended, and may not be offered or sold within the
United States absent registration or an exemption from the registration
requirements thereunder. This release does not constitute an offer to sell or
the solicitation of an offer to buy nor shall there be any sale of the
securities in any state in which such offer, solicitation or sale would be
unlawful.
About DiagnoCure
DiagnoCure specializes in the development, production and
commercialization of molecular diagnostics for the detection and management of
cancer. Its first test, ImmunoCyt(TM) / uCyt+(TM) for bladder cancer, is
distributed worldwide. In 2003, the Company entered into a strategic alliance
with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a
second generation PCA3-based diagnostic test for prostate cancer. This test is
now available in analyte specific reagent (ASR) format in the U.S. as well as
in Europe with full CE Mark. The Company plans to expand its product
portfolio, namely in prostate, lung and other cancers. In addition to its own
research, the Company intends to acquire or in-license promising cancer
biomarkers from both academic and commercial institutions. Additional
information can be found at www.diagnocure.com.
Forward-looking statements
This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects and future revenues are based on
management expectations. In addition, the reader is referred to the applicable
general risks and uncertainties described in DiagnoCure's most recent Annual
Information Form under the heading "Risk Factors". DiagnoCure undertakes no
obligation to publicly update or revise any forward-looking statements
contained herein.
%SEDAR: 00003671EF